Inhalation beta-2-agonists in cardiorespiratory pathology: pro-or anti-inflammatory effects?

Cover Page

Cite item

Full Text

Abstract

Currently, the increase in comorbid pathology, including patients with bronchoobstructive and cardiovascular diseases remains an urgent problem. Therefore, there is a need not only for new approaches in the tactics of management and treatment of patients with combined cardiorespiratory pathology, but also a more complete understanding of the impact of existing bronchodilator therapy on comorbid pathology and the pathophysiological changes taking place in order to create a new approach to the diagnosis and selection of effective and optimal treatment. The article provides a review of the literature on the impact of beta-2-agonists on pro- and anti-inflammatory mechanisms in patients with bronchial obstruction, including cardiovascular disease.

About the authors

S. Yu. Nistor

Moscow State University of Medicine and Dentistry a.n. A.I. Evdokimov

Author for correspondence.
Email: nistor.lana@mail.ru
ORCID iD: 0000-0002-8983-230X

науч. сотр. лаборатории пульмонологии отдела клинической медицины

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

E. V. Smolyakova

National Medical Research Center of Cardiology

Email: smolyakovak@mail.ru
ORCID iD: 0000-0002-1904-5319
SPIN-code: 1751-0230

аспирант отдела гипертонии ИКК им. А.Л. Мясникова

Russian Federation, 15a, 3rd Cherepkovskaya street, Moscow, 121552

A. A. Klimova

National Medical Research Center of Cardiology

Email: ruanna89@mail.ru
ORCID iD: 0000-0001-8320-3054
SPIN-code: 8251-6964

соискатель отдела гипертонии, врач-кардиолог приемного отделения ИКК им. А.Л. Мясникова

Russian Federation, 15a, 3rd Cherepkovskaya street, Moscow, 121552

A. V. Rvacheva

Moscow State University of Medicine and Dentistry a.n. A.I. Evdokimov

Email: arvatcheva@mail.ru
ORCID iD: 0000-0001-9277-2291
SPIN-code: 5267-9598

ведущий науч. сотр. лаборатории пульмонологии отдела клинической медицины

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473

K. A. Zykov

Moscow State University of Medicine and Dentistry a.n. A.I. Evdokimov; Research Institute of Pulmonology of the Federal Medical-Biological Agency of Russia

Email: kirillaz@inbox.ru
ORCID iD: 0000-0003-3385-2632
SPIN-code: 6269-7990

докт. мед. наук, профессор РАН, врио директора;  исполняющий обязанности заведующего кафедрой факультетской терапии и профессиональных болезней, заведующий лабораторией пульмонологии отдела клинической медицины 

Russian Federation, 20/1, Delegatskaya street, Moscow, 127473; 28, Orekchovy Boulevard, Moscow, 127473

References

  1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. doi: 10.1016/S0140-6736(12)61728-0.
  2. Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии // Рациональная фармакотерапия в кардиологии. — 2009. — Т.5. — №4. — С. 9–16. [Karoli NA, Rebrov AP. Comorbidity in patients with chronic obstructive pulmonary disease: a role of cardiovascular disorders. Rational pharmacotherapy in cardiology. 2009;5(4):9–16. (In Russ).]
  3. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med. 2002;166(3):333—339. doi: 10.1164/rccm.2110093.
  4. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–1959. doi: 10.1378/chest.127.6.1952.
  5. Dogra S, Ardern CI, Baker J. The relationship between age of asthma onset and cardiovascular disease in Canadians. J Asthma. 2007;44(10):849–854. doi: 10.1080/02770900701752391.
  6. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455–468. doi: 10.1016/0021-9681(70)90054-8.
  7. Valderas JM, Starfield B, Sibbald B, et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357–363. doi: 10.1370/afm.983.
  8. Parameswaran K, Todd DC, Soth M. Altered respiratory physiology in obesity. Can Respir J. 2006;13(4):203–210. doi: 10.1155/2006/834786.
  9. Fida NG, Enquobahrie DA, Gelaye B, et al. Associations of asthma with body mass index and adult weight change among reproductive age women. J Asthma. 2011;48(7):701–706. doi: 10.3109/02770903.2011.604885.
  10. Global Initiative for Asthma (GINA). What’s new in GINA 2016? Global strategy for asthma management and prevention. Update 2016. Available from: http://chicagoasthma.org/wp-content/uploads/2016/07/Whats-new-in-GINA-2016.pdf
  11. Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164(3):469–473. doi: 10.1164/ajrccm.164.3.2007149.
  12. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997;156(2 Pt 1):341–357. doi: 10.1164/ajrccm.156.2.9611013.
  13. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2(10):582–593. doi: 10.1038/ncpneph0283.
  14. Gan WQ, Paul Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest. 2005;127(2):558–564. doi: 10.1378/chest.127.2.558.
  15. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003;91(4A):9B–13B. doi: 10.1016/s0002-9149(02)03268-x.
  16. Gong HJr, Sioutas C, Linn WS. Controlled exposures of healthy and asthmatic volunteers to concentrated ambient particles in metropolitan Los Angeles. Res Rep Health Eff Inst. 2003;(118):1–36; discussion 37–47. doi: 10.1080/08958370304455.
  17. Valvi D, Mannino DM, Müllerova H, Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis. 2012;7:173–182. doi: 10.2147/COPD.S29892.
  18. Дронова Т.А., Поляков Д.В. Клиническая эффективность и влияние на цитокиновый статус комбинированной антигипертензивной терапии у больных артериальной гипертонией // Медицинская иммунология. — 2009. — Т.11. — №1. — С. 49–56. [Dronova TA, Polyakov DV. Clinical efficiency and influence of combined antihypertensive therapy upon cytokine profile in the patients with arterial hypertension. Meditsinskaia immunologiia. 2009;11(1):49–56. (In Russ).]
  19. Global Initiative for Chronic Obstructive Lung Disease (Revised 2014). Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких. Пересмотр 2014 г. Пер. с англ. М.: Российское респираторное общество; 2015. Доступно по: https://studfiles.net/preview/6200140/. Ссылка активна на 16.11.2018.
  20. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–192. doi: 10.1038/nri2254.
  21. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med. 2000;161(1):64–72. doi: 10.1164/ajrccm.161.1.9809100.
  22. Saha S, Brightling CE. Brightling eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47. doi: 10.2147/copd.2006.1.1.39.
  23. Li T, Ke Y, Cheng H, et al. [Reasearch progress on the role of neutrophils in asthma. (Article in Chinese).] Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016;45(5):544–549.
  24. Хмелева Е.В., Антонюк М.В., Калинина Е.П. Цитокиновый профиль и состояние иммунной системы у больных хронической обструктивной болезнью легких с сопутствующей артериальной гипертензией // Иммунология. — 2011. — Т.32. — №2. — С. 99–100. [Khmeleva EV, Antonyuk MV, Kalinina EP.The cytokine profile and immune status in patients presenting with chronic obstructive pulmonary disease and concomitant arterial hypertension. Immunologija. 2011;32(2):99–100. (In Russ).]
  25. Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous dis ease. Lancet. 2008;372(9643):1107–1119. doi: 10.1016/S0140-6736(08)61452-X.
  26. Lazarus SC, Boushey HA, Fahy JV, et al. Long-action beta2-agonist therapy with inhaled corticosteroids in patients with persistent: a randomized controlled trial. JAMA. 2001;285(20):2583–2593. doi: 10.1001/jama.285.20.2583.
  27. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504. doi: 10.1124/pr.111.004580.
  28. Зыков К.А., Овчаренко С.И. Подходы к лекарственной терапии больных ХОБЛ стабильного течения: предлагаемый алгоритм лечения // Медицинский совет. — 2015. — №17. — С. 24—31. [Zykov KA, Ovcharenko SI. Approaches to drug therapy in patients with stable COPD: suggested treatment algorithm. Meditsinskij sovet. 2015;(17):24–31. (In Russ).]
  29. Chu YT, Chang TT, Jong YJ, et al. Suppressive effects of formoterol and salmeterol on eotaxin-1 in bronchial epithelial cells. Pediatr Allergy Immunol. 2010;21(2 Pt 1):345–352. doi: 10.1111/j.1399-3038.2009.00906.x.
  30. Chien JW, Chu YT, Yang SN, et al. Long-acting beta 2 agonists suppress IP-10 expression in human bronchial epithelial cells. J Investig Med. 2012;60(7):1048–1053. doi: 10.2310/JIM.0b013e3182673ff9.
  31. Chiu JC, Hsu JY, Fu LS, et al. Comparison of the effects of two long-acting beta2-agonists on cytokine secretion by human airway epithelial cells. J Microbiol Immunol Infect. 2007;40(5):388–394.
  32. Spoelstra FM, Postma DS, Hovenga H, et al. Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts. Eur Respir J. 2000;15(1):68–74. doi: 10.1034/j.1399-3003.2000.15a13.x.
  33. Rüdiger JJ, Gencay M, Yang JQ, et al. Fast beneficial systemic anti-inflammatory effects of inhaled budesonide and formoterol on circulating lymphocytes in asthma. Respirology. 2013;18(5):840–847. doi: 10.1111/resp.12104.
  34. Abraha D, Cho SH, Agrawal DK, et al. (S,S)-formoterol increases the production of IL-4 in mast cells and the airways of a murine asthma model. Int Arch Allergy Immunol. 2004;133(4):380–388. doi: 10.1159/000077358.
  35. Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med. 1998;157(1):184–191. doi: 10.1164/ajrccm.157.1.9704070.
  36. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy. 2002;32(2):264–269. doi: 10.1046/j.1365-2222.2002.01286.x.
  37. Stelmach I, Gorski P, Jerzynska J, et al. A randomized, double-blind trial of the effect of treatment with formoterol on clinical and inflammatory parameters of asthma in children. Ann Allergy Asthma Immunol. 2002;89(1):67–73. doi: 10.1016/S1081-1206(10)61913-8.
  38. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest. 2005;128(4):1936–1942. doi: 10.1378/chest.128.4.1936.
  39. Долгушева Ю.А. Применение селективных бета-адреномиметиков с разной продолжительностью действия у пациентов с арте- риальной гипертонией в сочетании с бронхообструктивной патологией: Автореф. дис. … канд. мед. наук. — М.; 2015. [Dolgusheva YuA. Primenenie selektivnykh beta-adrenomimetikov s raz- noj prodolzhitel’nost’yu dejstviya u patsientov s arte- rial’noj gipertoniej v sochetanii s bronkho- obstruktivnoj patologiej. [dissertation abstract] Moscow; 2015. (In Russ).] Доступно по: http://medical-diss.com/medicina/primenenie-selektivnyh-beta-adrenomimetikov-s-raznoy-prodolzhitelnostyu-deystviya-u-patsientov-s-arterialnoy-gipertoniey-. Ссылка активна на 14.12.2018.
  40. Cao Y, Gong W, Zhang H, et al. A comparison of serum and sputum inflammatory mediator profiles in patients with asthma and COPD. J Int Med Res. 2012;40(6):2231–2242. doi: 10.1177/030006051204000621.
  41. Singh D, Roche N, Halpin D, et al. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(5):541–549. doi: 10.1164/rccm.201606-1179PP.

Copyright (c) 2018 Nistor S.Y., Smolyakova E.V., Klimova A.A., Rvacheva A.V., Zykov K.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies